Trial Profile
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of MK3207 in the Treatment of Acute Migraine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 3207 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck & Co; Merck Sharp & Dohme
- 28 Apr 2012 Planned number of patients changed from 522 to 685 as reported by European Clinical Trials Database record.
- 28 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database record.
- 24 Feb 2009 Actual end date changed from 1 Jan 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.